We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Niox Group Plc | LSE:NIOX | London | Ordinary Share | GB00BJVD3B28 | ORD 0.08P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 70.20 | 5,257,667 | 16:35:29 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 69.80 | 70.60 | 71.20 | 70.00 | 71.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 33.3M | 16.1M | 0.0383 | 18.28 | 294.31M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:29 | O | 100,000 | 70.125 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 01/5/2024 | 07:00 | UK RNS | Niox Group PLC Total Voting Rights Update |
| 29/4/2024 | 17:00 | UK RNS | Niox Group PLC Grant of SAYE options |
| 22/4/2024 | 16:37 | UK RNS | Niox Group PLC Notice of 2024 Annual General Meeting |
| 05/4/2024 | 15:10 | UK RNS | Niox Group PLC Director/PDMR Shareholding |
| 04/4/2024 | 14:10 | UK RNS | Niox Group PLC Dividend Timetable |
| 03/4/2024 | 13:00 | UK RNS | Niox Group PLC Director/PDMR Shareholding |
| 03/4/2024 | 09:00 | UK RNS | Niox Group PLC Replacement: Block listing Interim Review |
| 02/4/2024 | 17:50 | UK RNS | Niox Group PLC Block listing Interim Review |
| 02/4/2024 | 13:45 | UK RNS | Niox Group PLC Replacement: Director/PDMR Shareholding |
| 28/3/2024 | 16:45 | UK RNS | Niox Group PLC Director/PDMR Shareholding |
Niox (NIOX) Share Charts1 Year Niox Chart |
|
1 Month Niox Chart |
Intraday Niox Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 03/5/2024 | 11:11 | NIOX GROUP - expertise in asthma diagnosis and management | 175 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-05-03 16:54:50 | 70.13 | 100,000 | 70,125.00 | O |
| 2024-05-03 16:15:01 | 70.93 | 1,650,000 | 1,170,328.50 | O |
| 2024-05-03 16:15:01 | 70.93 | 1,650,000 | 1,170,328.50 | O |
| 2024-05-03 16:15:01 | 71.00 | 1,618,563 | 1,149,179.73 | O |
| 2024-05-03 15:35:29 | 70.20 | 8,941 | 6,276.58 | UT |
| Top Posts |
|---|
Posted at 02/5/2024 08:37 by earwacks Have been delving further back into Circassia history. This is looking one of the more bizar Aim stories and there have been many. Apparently cir floated at £3.60 back in the day. Something to do with cat allergies! Thats me. My partner has two. Nightmare, but we also have a dog to defend me. Anyway obviously cir was a complete crackpot company under old management and got badly tangled up with Astra. Guess who came out on top? However Ian Johnson, like Chris Mills I clocked when he took Bioquel on a very successful journey about the same time as Cir were in their early days. Quite how Johnson came to Cir to take the reigns I’m not sure, but he certainly worked his magic on it. Just watched an old video of Andy Brough (schroders)talking about how he always gets interested when he hears Chris Mills is involved on the board of a biotech. I remember Mills saying all the serious money had been made on Niox when it was 50p, and it couldnt make 60p under its own steam, inferring a buyout I guess. It went on up to 75p under its own steam with a little help from a special dividend payout. Subsequently it fell back a bit. People keep saying its expensive, but I feel that is only when looking at current valuations. I remember valuations in companies being a lot higher than this pre Covid. Recently Niox have offered employees a 3 year savings plan for shares at 51p which I find curious. In light of recent developments with COPD, the upgrading of a new FeNo diagnostic instrument (the old one having a 5 year max shelf life limit) and the development of a home diagnostic kit, I find myself thinking these shares are bloody cheap still. Incidentally Mills is on the board of EKF (I have a smaller portion) and has made two £100,000 this year, one very recently when they announced results which as expected were not great. But they make enzymes! Or are trying to. He also has connections with Vrci and Renx, (kidney diagnostics) both of which have come off the boil a bit. Tempted for a small position, but they would definitely stretch my risk appetite. And why not just stick with what you know, Niox! |
Posted at 30/4/2024 08:58 by earwacks Edward. Sounds fantastic. If successful that doubly underestimates the potential for Niox. Even Chris Mills seems to have not understood Niox. I think it was last year he commented Niox couldn’t reach 60p under its own steam! It smashed through that in a couple of months. He has been very bullish and it was him that flagged up the humongous tax credit. Personally I thought a target by one broker of £1.20 under its own steam was not pie in the sky considering 95 percent of their market is up for grabs. Requires replacing every 5 years depending on usage. Mills did point out this is a razor blade stock. Sounds like they have also reinvented another Gillette. dividend declared for next months and possibly another special on the cards. Have to admit this is now about a third of my portfolio and am not interested in top slicing. I have a few duffers in my portfolio but would rather kick them out frankly. My best pick since Arm holdings. Gl |
Posted at 27/4/2024 15:19 by earwacks Astra dissolved their partnership with Circassia over Tudorza and Duklar inhaler for COPD.Astra retained commercial rights in consideration of 150 million dollar debt and retained 18 percent of Circassia, now Niox. Astra have since offloaded this product. Not sure how successful it has been. Probably nothing like the FeNo tester. What Niox have is the development of the best Asthma diagnostic device and 600 million tax credit for the Circassia debacle. Meaning they will never pay tax on their very cash generative device. The tax credit is also transferable which makes it an added asset to their £270 million market cap. The directors are probably nearing retirement. They have built a highly profitable business from the wreckage of Circassia, making it a market leader in its field, but still only tapping 5 percent of possible world market. Added to that they are developing a domestic kit, which if successful will probably appeal to a us pharma giant, not necessarily just Astra, who as you say may not be interested as it is Gsk that have recently purchased a company that have developed an asthma drug. Potential for Niox is pretty big and are at an interesting stage where they might need some serious gearing up to reach potential global markets, whilst having converted themselves into a growing cash machine. Although expensive on last years results I don’t think forecasters have quite got their head around the potential of Niox yet |
Posted at 26/4/2024 19:13 by earwacks Another 3 half million pound late reported buys this morning and forty bot trades of 2 or less shares drags the price back. No RNS for all these big trades this week. |
Posted at 23/2/2024 18:18 by earwacks I think it’s held up well considering The uk is the worst performing market in the world and many British companies make most of their money in global business.This is a recent high for NIOX. It is similar to share price movement last year between update and actual results. News on dividend and cash position should help re establish the share price Then of course there is the expectant takeover by AZN Why else would they hold 16 percent of the. Company? Gl all |
Posted at 10/1/2024 07:51 by earwacks Niox would be the perfect complement in diagnosing severe asthma and managing the right level of treatment surely. FeNo being the gold standard in accurately measuring the exact inflammation of the airways |
Posted at 09/1/2024 22:45 by p1nkfish Noted the GSK addition to their asthma portfolio today.I no longer hold NIOX but wish you all well. |
Posted at 19/12/2023 06:03 by earwacks Paul Hill catches up with GuyHarwood on his various funds. Brief mention of Niox and the home kit. Suggests they would need a partner to get this to retail. Well we know for a fact they have set aside money ( 2 million) for the home kit, and aside from that it sounds like the accelerating cash generation is set to continue with solid dividend cover. I listen with great interest to his other life science projects which all seem to need funding in some way at a very difficult time.They have no tax to pay for yonks due to the unbelievable tax loss carry over of 600 million! So what are they going to do with the ever expanding cash pile? Richard Griffiths still reducing gradually and still the largest holder. Clearly someone is happy to take them off his hands but maybe what has halted the rise of the share price for now. With the share price seemingly consolidating around this level looks a good opportunity to add. As keen as I am to diversify, I just can’t see a better case for investing than here. I particularly like that they don’t really push this stock. They don’t need to, the numbers do the talking! Still up for a buy out but the sales will quickly catch up the premium rating PE of 22, not actually that expensive for a company with high teens revenue growth and great margins with recurring refill product. Gl |
Posted at 25/8/2023 10:09 by joseph moran DividendNIOX Niox Group AIM 2.5p 07-Jun-23NIOX 07-Jun-23 Dividend Announcement Ex-Dividend Date 17-Aug-23 Payment Date 15-Sep-23 |
Posted at 18/5/2023 07:08 by bc4 NIOX GROUP PLCAGM Statement Oxford, UK - 18 May 2023: NIOX Group plc (AIM: NIOX), a medical device company focused on point of care asthma diagnosis and management, is holding its Annual General Meeting today at the Hayakawa Building, Edmund Halley Road, Oxford Science Park. Oxford OX4 4GB. Trading Update We are pleased to report that our business has continued to perform well, with total revenues in the first 4 months of the year up 21% compared with the same period in 2022. Our core Clinical business grew strongly with revenues up 28% compared with the same period in 2022. EMEA has continued to experience strong growth, and our Asia markets have also improved significantly. In the USA, our relatively new distributor partners are starting to make an increasing contribution to revenues in the region, which were up 16% year to date compared with 2022.Ian Johnson, NIOX's Executive Chairman, said: "I am pleased to report a continuing strong trading performance in the year to date, reflecting the successful execution of our strategy. The effect of the growth in revenues, robust margins and the lower level of overheads means that adjusted EBITDA for the full year is now likely to be significantly higher than management expectations at the start of the year. The Board believes that the cash generation and resources of the Group are now at a level where it is appropriate to commence the payment of a dividend. Further details of the timing and quantum of an initial dividend payment will be announced in due course. It does not get any better than that great update |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
